graph EGM comparisons
atezolizumab alonetitleno additional treatmenttitlegemcitabine plus platintitleStandard of Care (SoC)titleIMvigor-010, 2021 NCT02450331 MIBC - NA - all population 406/403IMvigor-130 (At-arm B vs Ch-armC), 2020 NCT02807636 mUC - L1 - all population 360/400IMvigor-211 (all population), 2018 NCT02302807 mUC - L2 - all population 467/464IMvigor-211 (PDL1>5%), 2018 NCT02302807 mUC - L2 - PDL1 positive 116/118IMvigor-211 (PDL1>1%), 2018 NCT02302807 mUC - L2 - PDL1 positive 316/309

Pathology:  MIBC - NA - all population;   mUC - L1 - all population;   mUC - L2 - all population;   mUC - L2 - PDL1 positive; 

MIBC - NA - all populationmUC - L1 - all populationmUC - L2 - all populationmUC - L2 - PDL1 positive
IMvigor-010, 2021IMvigor-130 (At-arm B vs Ch-armC), 2020IMvigor-211 (all population), 2018IMvigor-211 (PDL1>5%), 2018IMvigor-211 (PDL1>1%), 2018
atezolizumab alone5T1T1T1T1T1
no additional treatment0T0
gemcitabine plus platin0T0
Standard of Care (SoC)0T0T0T0